Related Experiment Video
Updated: Aug 2, 2026

Microscale Vortex-assisted Electroporator for Sequential Molecular Delivery
Published on: August 7, 2014
The emerging use of the 20-microg oral contraceptive
1Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX 77030-3498, USA. alfredp@bcm.tmc.edu
Objective:
To highlight studies that investigated the efficacy, safety, and tolerability of low-dose oral contraceptives (OCs) containing 20 microg of ethinyl estradiol (EE) and to discuss the use of these low-dose contraceptives in women from adolescence to menopause and the noncontraceptive health benefits likely to be afforded by low-dose contraceptives.
Design:
Relevant literature was identified by searching MEDLINE and EMBASE. Other sources were located by consulting the bibliographies of the material collected from Medline and EMBASE. Sources for additional information included documents from the United States Food and Drug Administration and the Physicians' Desk Reference (54th ed.).
Conclusion(S):
The current lowest available dose of EE used for OCs in the United States is 20 microg. Formulations with 20 microg of EE are efficacious and have a low incidence of estrogen-related side effects. Since this lowest effective EE dose inhibits ovarian activity, 20 microg of EE should also provide the noncontraceptive health benefits of OCs. Both contraceptive and noncontraceptive benefits of OCs are available to most women from adolescence to menopause without complications.
More Related Videos
04:28Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
Published on: March 23, 2016
09:34Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Related Concept Videos
Birth Control Methods
Oral Drug Delivery Systems: Introduction
Oral Drug Delivery Systems: Continuous-Release Systems
Oral Drug Delivery Systems: Delayed-Release Systems
Intrauterine Drug Delivery Systems
Oral Hypoglycemic Agents: Biguanides and Glitazones